Results 81 to 90 of about 1,197 (161)

Enhancement of Th1 immune responses to recombinant influenza nucleoprotein by Ribi adjuvant [PDF]

, 2013
A broad coverage influenza vaccine against multiple viral strains based on the viral nucleoprotein (NP) is a goal pursued by many laboratories. If the goal is to formulate the vaccine with recombinant NP it is essential to count on adjuvants capable ...
Alvarez, Paula, Boado, Lorena Analía, Cargnelutti, Diego Esteban, Mattion, Nora Marta, Sanchez, María Victoria, Scodeller, Eduardo   +5 more
core  

The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge

Vaccine, 2017
Two cationic liposomal adjuvants CAF01 and CAF09 were formulated with the native or the recombinant Chlamydia muridarum major outer membrane protein (nMOMP and rMOMP). BALB/c mice were immunized with the four vaccine formulations using the subcutaneous followed by the intranasal (i.n.) routes. As positive controls mice were inoculated i.n. with live C.
Pal, Sukumar, Tifrea, Delia F, Follmann, Frank, Andersen, Peter, de la Maza, Luis M   +4 more
openaire   +4 more sources

Th1/Th17 T cell Tissue-Resident Immunity Increases Protection, But Is Not Required in a Vaccine Strategy Against Genital Infection With Chlamydia trachomatis

Frontiers in Immunology, 2021
The requirement for vaccine-induced tissue-resident immunity for protection against one or repeated infections with Chlamydia trachomatis (C.t.) is still not fully resolved.
Nina Dieu Nhien Tran Nguyen, Safia Guleed, Anja Weinreich Olsen, Frank Follmann, Jan Pravsgaard Christensen, Jes Dietrich   +5 more
doaj   +1 more source

Intranasal vaccination with killed Leishmania amazonensis promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB/c mice challenged with Leishmania (infantum) chagasi.

Parasitology, 2015
SUMMARYThe CAF01 adjuvant has previously been shown to be safe for human use and to be a potent adjuvant for several vaccine antigens. In the present work, we sought to optimize the Leishmania amazonensis antigens (LaAg) intranasal vaccine in an attempt to enhance the protective immune responses against Leishmania (infantum) chagasi by using the CAF01 ...
Janine Miranda, Leal, Marcelle, Mosquini, Luciana Polaco, Covre, Nataly Pescinalli, Stagmiller, Rodrigo Ribeiro, Rodrigues, Dennis, Christensen, Herbert Leonel, de Matos Guedes, Herbert Leonel De Matos, Guedes, Bartira, Rossi-Bergmann, Daniel Cláudio De Oliviera, Gomes   +9 more
openaire   +2 more sources

Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis. [PDF]

PLoS ONE, 2016
The search for new and improved tuberculosis (TB) vaccines has focused on IFN-γ both for selecting antigens and for evaluating vaccine delivery strategies.
Rolf Billeskov, Esterlina V Tan, Marjorie Cang, Rodolfo M Abalos, Jasmin Burgos, Bo Vestergaard Pedersen, Dennis Christensen, Else Marie Agger, Peter Andersen   +8 more
doaj   +1 more source

A Lipid Based Antigen Delivery System Efficiently Facilitates MHC Class-I Antigen Presentation in Dendritic Cells to Stimulate CD8+ T Cells [PDF]

, 2016
The most effective strategy for protection against intracellular infections such as Leishmania is vaccination with live parasites. Use of recombinant proteins avoids the risks associated with live vaccines. However, due to low immunogenicity, they fail
A Brave, A Homhuan, A Pashine, A Rodriguez, A Sexton, AL Ackerman, B Guy, C Trumpfheller, C Watts, CR Casella, D Yang, DL Daleke, DM Smith, EJ Feldman, EM Agger, F Sallusto, I Mellman, IM Hafez, J Davidsen, JA Hubbell, JA Villadangos, JE Boudreau, JJ Moon, K Inaba, K Jain, K Kataoka, KD Lee, KK Peachman, KS Korsholm, L Flatz, L Kedzierski, L Krishnan, L Krishnan, L Leserman, L Van Kaer, MD Joshi, MJ Heffernan, OH Lowry, OP Joffre, P Bryant, P Nordly, R Ravindran, RA Schwendener, RM Steinman, RM Straubinger, S Bhowmick, S Nair, S Sinha, SA Plotkin, SG Reed, SG Reed, SR Cardoso, T Mazumdar, T Nakamura, V Mata-Haro, VP Torchilin, Y Tanaka   +56 more
core   +1 more source

Modulation of primary immune response by different vaccine adjuvants

Frontiers in Immunology, 2016
Adjuvants contribute to enhancing and shaping the vaccine immune response through different modes of action. Since the primary immune response can influence the overall quality of the response generated, here we investigate early biomarkers of ...
Annalisa Ciabattini, Elena Pettini, Fabio Fiorino, Gabiria Pastore, Peter Andersen, Gianni Pozzi, Donata Medaglini   +6 more
doaj   +1 more source

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

The Lancet Infectious Diseases, 2019
Chlamydia is the most common sexually transmitted bacterial infection worldwide. National screening programmes and antibiotic treatment have failed to decrease incidence, and to date no vaccines against genital chlamydia have been tested in clinical trials.
Abraham, S, Juel, HB, Bang, P, Cheeseman, HM, Dohn, RB, Cole, T, Kristiansen, MP, Korsholm, KS, Lewis, D, Olsen, AW, McFarlane, LR, Day, S, Knudsen, S, Moen, K, Ruhwald, M, Kromann, I, Andersen, P, Shattock, RJ, Follmann, F   +18 more
openaire   +4 more sources

Protective Effect of Vaccine Promoted Neutralizing Antibodies against the Intracellular Pathogen Chlamydia trachomatis

Frontiers in Immunology, 2017
There is an unmet need for a vaccine to control Chlamydia trachomatis (C.t.) infections. We have recently designed a multivalent heterologous immuno-repeat 1 (Hirep1) vaccine construct based on major outer membrane protein variable domain (VD) 4 regions ...
Anja Weinreich Olsen, Emma Kathrine Lorenzen, Ida Rosenkrands, Frank Follmann, Peter Andersen   +4 more
doaj   +1 more source

Aerodynamic engineering of a pulmonary prime-pull vaccine against Tuberculosis [PDF]

, 2018
Tuberculosis (TB) remains the infectious disease with the highest mortality alongside HIV. Despite the existence of the Bacillus Calmette-Guerin (BCG) vaccine there is an unmet need for an effective vaccine against pulmonary TB, the most common form of ...
Roces Rodriguez, Carla Belen.
core   +2 more sources